Tirzepatide Test Kit: Which Tests Matter and Why

What the trial data tell us about pre-treatment baseline checks

The SURMOUNT-1 trial, published in the New England Journal of Medicine and forming a central part of NICE's appraisal of tirzepatide (TA1026), enrolled adults with a BMI of 30 or above (or 27 with at least one weight-related condition) and excluded participants with specific conditions, including a personal or family history of medullary thyroid carcinoma, active gallbladder disease, or severe gastrointestinal disorders. That exclusion process is not a kit you can open at home; it is a clinical conversation and, where needed, targeted blood work.

Participants' baseline characteristics included documented weight, BMI, HbA1c (to confirm absence of type 2 diabetes in that cohort), and markers of cardiometabolic health. The reason is straightforward: tirzepatide acts on two gut-hormone receptors and slows gastric emptying, so the starting picture of your metabolism matters. A prescriber who skips that picture is working blind.

In clinical practice, the tests ordered before starting tirzepatide commonly include HbA1c or fasting glucose, kidney function (eGFR and creatinine), liver function tests, and a lipid panel. None of these requires a specialist clinic, a GP or a private prescribing service can request them. What they collectively do is confirm that the licensed eligibility criteria are met and that no contraindication has been missed.

Why searches for a 'test kit' are often really asking about at-home monitoring options

Many people searching for a tirzepatide kit are thinking about one of two things: a home blood-test kit to check their own markers before a consultation, or a drug-detection test to find out whether tirzepatide shows up on workplace screening. Both are reasonable questions with distinct answers.

For the first: several UK private laboratories offer finger-prick or venepuncture home kits measuring HbA1c, liver enzymes, kidney function and lipids, the sorts of markers relevant to a tirzepatide assessment. These are not tirzepatide-specific kits; they are general metabolic panels. They can be useful context to bring to a consultation, but they do not replace it. A prescriber still needs to review your full medical history, current medicines (oral contraceptives, for instance, may need a back-up method for the first four weeks of treatment and after each dose increase, because tirzepatide can reduce pill absorption), and body-weight evidence.

For the second question (drug testing) tirzepatide does not appear on standard workplace drug screens, which target substances such as opioids, benzodiazepines and stimulants. If you need specific information on that, our page on tirzepatide and drug testing covers it in detail. The at-home monitoring options for tirzepatide page looks at home blood-test services and what they can and cannot tell you.

Blood tests during tirzepatide treatment: what monitoring actually looks like

Once treatment begins, the NHS medicines page for tirzepatide and the Summary of Product Characteristics both recommend that prescribers monitor relevant parameters at intervals, particularly in people with type 2 diabetes (where blood-glucose control may change significantly as weight falls) and in those with existing kidney or liver conditions.

In practice this means periodic HbA1c or glucose checks if you have diabetes or prediabetes, and attention to any symptom that might signal a rare but serious complication, pancreatitis, for instance, presents as severe stomach pain that can radiate to the back and requires prompt medical assessment. It does not mean monthly full-blood panels for everyone; clinical review is proportionate to individual risk factors.

At nume, every repeat order is clinically re-reviewed by a GPhC-registered prescriber (a real clinician reads your case, not an automated queue) before any further supply is approved. That review considers how your weight and symptoms have changed, not just whether you've run out of pen. If you're thinking about what monitoring might look like for you personally, the tirzepatide blood test guidance page goes further on specific markers and timing. You can also browse a broader overview of weight-loss treatment options to understand where tirzepatide sits alongside other licensed approaches.

Getting assessed the right way in the UK

The phrase 'test kit' implies a shortcut to starting treatment. There isn't one, not because the system is unnecessarily bureaucratic, but because a medicine that reshapes appetite, slows digestion and influences blood-sugar regulation genuinely warrants individual assessment. The eligibility criteria in NICE TA1026's recommendations chapter exist for the same reason: BMI thresholds and comorbidity lists are a proxy for 'this person is likely to benefit and unlikely to be harmed'.

Private routes, including a consultation with a service like ours, work the same way. You don't need a referral or a waiting list, but you do need a prescriber to assess you. Ours do that the same day an application comes in. The Mounjaro price comparison page covers what different private services include in their quoted fees, worth reading before you decide, because consultation, clinical review and aftercare vary considerably across providers. Our clinical team's approach is described on the clinical team page if you want to understand who signs off prescriptions at nume.

If you have questions before you apply, the FAQs page addresses the most common ones, or you can contact the team directly. When you're ready to take the next step, start your free consultation, it costs nothing, and the clinical review happens the same day.